Increased uptake of doxorubicin by cells undergoing heat stress does not explain its synergistic cytotoxicity with hyperthermia

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics. CA: Cancer J Clin. 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Murphy GP, Lawrence W, Lenhard RE. 1995. American Cancer Society Textbook of Clinical Oncology. 2nd ed. Atlanta, GA: The American Cancer Society.
   Google Scholar
• Zhang M, Xiao B, Wang H, et al. Edible ginger-derived nano-lipids loaded with doxorubicin as a novel drug-delivery approach for colon cancer therapy. Mol Ther. 2016;24:1783–1796.
   PubMed Web of Science ®Google Scholar
• Banerjee A, Pathak S, Vasan D, et al. Strategies for targeted drug delivery in treatment of colon cancer: current trends and future perspectives. Drug Discov Today. 2017;22:1224–1232.
   PubMed Web of Science ®Google Scholar
• Kim S, Kim JH. Lethal effect of adriamycin on the division cycle of HeLa cells. Cancer Res. 1972;32:323–325.
   PubMed Web of Science ®Google Scholar
• Meriwether WD, Bachur NR. Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia. Cancer Res. 1972;32:1137–1142.
   PubMed Web of Science ®Google Scholar
• Wang JJ, Chervinsky DS, Rosen JM. Comparative biochemical studies of adriamycin and daunomycin in leukemic cells. Cancer Res. 1972;32:511–515.
   PubMed Web of Science ®Google Scholar
• Momparler RL, Karon M, Siegel SE, et al. Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res. 1976;36:2891–2895.
   PubMed Web of Science ®Google Scholar
• Bachur NR, Gordon SL, Gee MV. Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation. Mol Pharmacol. 1977;13:901–910.
   PubMed Web of Science ®Google Scholar
• Berlin V, Haseltine WA. Reduction of adriamycin to a semiquinone-free radical by NADPH cytochrome P-450 reductase produces DNA cleavage in a reaction mediated by molecular oxygen. J Biol Chem. 1981;256:4747–4756.
   PubMed Web of Science ®Google Scholar
• Bates DA, Winterbourn CC. Deoxyribose breakdown by the adriamycin semiquinone and H2O2: evidence for hydroxyl radical participation. FEBS Lett. 1982;145:137–142.
   PubMed Web of Science ®Google Scholar
• Griffin-Green EA, Zaleska MM, Erecińska M. Adriamycin-induced lipid peroxidation in mitochondria and microsomes. Biochem Pharmacol. 1988;37:3071–3077.
   PubMed Web of Science ®Google Scholar
• Sinha BK, Trush MA, Kennedy KA, et al. Enzymatic activation and binding of adriamycin to nuclear DNA. Cancer Res. 1984;44:2892–2896.
   PubMed Web of Science ®Google Scholar
• Skladanowski A, Konopa J. Relevance of interstrand DNA crosslinking induced by anthracyclines for their biological activity. Biochem Pharmacol. 1994;47:2279–2287.
   PubMed Web of Science ®Google Scholar
• Tewey KM, Rowe TC, Yang L, et al. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984;226:466–468.
   PubMed Web of Science ®Google Scholar
• Capranico G, Dasdia T, Zunino F. Comparison of doxorubicin‐induced DNA damage in doxorubicin‐sensitive and‐resistant P388 murine leukemia cells. Int J Cancer. 1986;37:227–231.
   PubMed Web of Science ®Google Scholar
• Lawrence TS. Reduction of doxorubicin cytotoxicity by ouabain: correlation with topoisomerase-induced DNA strand breakage in human and hamster cells. Cancer Res. 1988;48:725–730.
   PubMed Web of Science ®Google Scholar
• Pang B, Qiao X, Janssen L, et al. Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat Commun. 2013;4:1908.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP–dependent transporters. Nat Rev Cancer. 2002;2:48–58.
   PubMed Web of Science ®Google Scholar
• Li J, Liu H, Yu J, et al. Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor β signaling in HCT116 colon cancer cells. Mol Med Rep. 2015;12:192–198.
   PubMed Web of Science ®Google Scholar
• Rosanò L, Cianfrocca R, Spinella F, et al. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res. 2011;17:2350–2360.
   PubMed Web of Science ®Google Scholar
• Bastid J. EMT in carcinoma progression and dissemination: facts, unanswered questions, and clinical considerations. Cancer Metastasis Rev. 2012;31:277–283.
   PubMed Web of Science ®Google Scholar
• van der Zee J, González D, van Rhoon GC, et al. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Lancet. 2000;355:1119–1125.
   PubMed Web of Science ®Google Scholar
• Harima Y, Ohguri T, Imada H, et al. A multicentre randomised clinical trial of chemoradiotherapy plus hyperthermia versus chemoradiotherapy alone in patients with locally advanced cervical cancer. Int J Hyperthermia. 2016;32:801–808.
   PubMed Web of Science ®Google Scholar
• Datta NR, Rogers S, Klingbiel D, et al. Hyperthermia and radiotherapy with or without chemotherapy in locally advanced cervical cancer: a systematic review with conventional and network meta-analyses. Int J Hyperthermia. 2016;32:809–821.
   PubMed Web of Science ®Google Scholar
• Krawczyk PM, Eppink B, Essers J, et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci. 2011;108:9851–9856.
   PubMed Web of Science ®Google Scholar
• Oei AL, Vriend LE, Crezee J, et al. Effects of hyperthermia on DNA repair pathways: one treatment to inhibit them all. Radiat Oncol. 2015;10:165.
   PubMed Web of Science ®Google Scholar
• Issels RD. Hyperthermia adds to chemotherapy. Eur J Cancer. 2008;44:2546–2554.
   PubMed Web of Science ®Google Scholar
• Cotte E, Glehen O, Mohamed F, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for chemoresistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg. 2007;31:1813–1820.
   PubMed Web of Science ®Google Scholar
• Yokoyama G, Fujii T, Ogo E, et al. Advanced chemoresistant breast cancer responding to multidisciplinary treatment with hyperthermia, radiotherapy, and intraarterial infusion. Int J Clin Oncol. 2004;10:139–143.
   Google Scholar
• Kimura-Tsuchiya R, Ishikawa T, Kokura S, et al. The inhibitory effect of heat treatment against Epithelial-Mesenchymal Transition (EMT) in human pancreatic adenocarcinoma cell lines. J Clin Biochem Nutr. 2014;55:56–61.
   PubMed Web of Science ®Google Scholar
• Hahn GM, Braun J, Har-Kedar I. Thermochemotherapy: synergism between hyperthermia (42-43 degrees) and adriamycin (of bleomycin) in mammalian cell inactivation. Proc Natl Acad Sci. 1975;72:937–940.
   PubMed Web of Science ®Google Scholar
• Mizuno S, Amagai M, Ishida A. Synergistic cell killing by antitumor agents and hyperthermia in cultured cells. Gan. 1980;71:471–478.
   PubMedGoogle Scholar
• Hahn GM, Strande DP. Cytotoxic effects of hyperthermia and adriamycin on Chinese hamster cells 2. J Natl Cancer Inst. 1976;57:1063–1067.
   PubMed Web of Science ®Google Scholar
• Rotstein LE, Daly J, Rozsa P. Systemic thermochemotherapy in a rat model. Can J Surg. 1983;26:113–116.
   PubMed Web of Science ®Google Scholar
• Dahl O. Hyperthermic potentiation of doxorubicin and 4′-epi-doxorubicin in a transplantable neurogenic rat tumor (BT4A) in BD IX rats. Int J Radiat Oncol Biol Phys. 1983;9:203–207.
   PubMed Web of Science ®Google Scholar
• Marmor JB, Kozak D, Hahn GM. Effects of systemically administered bleomycin or adriamycin with local hyperthermia on primary tumor and lung metastases. Cancer Treat Rep. 1979;63:1279–1290.
   PubMedGoogle Scholar
• Rossi CR, Vecchiato A, Foletto M, et al. Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas. Cancer. 1994;73:2140-2140.
   Web of Science ®Google Scholar
• Harrison LE, Bryan M, Pliner L, et al. Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy. Ann Surg Oncol. 2008;15:1407–1413.
   PubMed Web of Science ®Google Scholar
• Hompes D, D’Hoore A, Cutsem E, et al. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian Multicentre Prospective Phase II Clinical Study. Ann Surg Oncol. 2012;19:2186–2194.
   PubMed Web of Science ®Google Scholar
• Polom K, Marano L, Roviello G, et al. Evolution and emerging future of cytoreducxtive surgery and hyperthermic intraperitoneal chemoperfusion in gastric cancer: from treating the incurable to preventing recurrence. Int J Hyperther. 2016;32:173–179.
   PubMed Web of Science ®Google Scholar
• González-Moreno S, González-Bayón LA, Ortega-Pérez G. Hyperthermic intraperitoneal chemotherapy: rationale and technique. World J Gastrointest Oncol. 2010;2:68–75.
   PubMed Web of Science ®Google Scholar
• Gewirtz D. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 1999;57:727–741.
   PubMed Web of Science ®Google Scholar
• Kawai H, Minamiya Y, Kitamura M, et al. Direct measurement of doxorubicin concentration in the intact, living single cancer cell during hyperthermia. Cancer. 1997;79:214–219.
   PubMed Web of Science ®Google Scholar
• Kong G, Anyarambhatla G, Petros WP, et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res. 2000;60:6950–6957.
   PubMed Web of Science ®Google Scholar
• Franken NA, Rodermond HM, Stap J, et al. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1:2315.
   PubMed Web of Science ®Google Scholar
• Sapareto SA, Dewey WC. Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys. 1984;10:787–800.
   PubMed Web of Science ®Google Scholar
• Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys. 1979;5:85–91.
   PubMed Web of Science ®Google Scholar
• Gillette EL. Clinical use of thermal enhancement and therapeutic gain for hyperthermia combined with radiation or drugs. Cancer Res. 1984;44:4836s–4841s.
   PubMed Web of Science ®Google Scholar
• Roizin-Towle L, Pirro JP. The response of human and rodent cells to hyperthermia. Int J Radiat Oncol Biol Phys. 1991;20:751–756.
   PubMed Web of Science ®Google Scholar
• Dewhirst MW, Viglianti BL, Lora-Michiels M, et al. Basic principles of thermal dosimetry and thermal thresholds for tissue damage from hyperthermia. Int J Hyperthermia. 2003;19:267–294.
   PubMed Web of Science ®Google Scholar
• Schrek R. Sensitivity of normal and leukemic lymphocytes and leukemic myeloblasts to heat. J Natl Cancer Inst. 1966;37:649–654.
   PubMedGoogle Scholar
• Viglianti BL, Dewhirst MW, Abraham JP, et al. Rationalization of thermal injury quantification methods: application to skin burns. Burns. 2014;40:896–902.
   PubMed Web of Science ®Google Scholar
• Franckena M, Fatehi D, de Bruijne M, et al. Hyperthermia dose-effect relationship in 420 patients with cervical cancer treated with combined radiotherapy and hyperthermia. Eur J Cancer. 2009;45:1969–1978.
   PubMed Web of Science ®Google Scholar
• Jones EL, Oleson JR, Prosnitz LR, et al. Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol. 2005;23:3079–3085.
   PubMed Web of Science ®Google Scholar
• van Rhoon GC. Is CEM43 still a relevant thermal dose parameter for hyperthermia treatment monitoring? Int J Hyperthermia. 2016;32:50–62.
   PubMed Web of Science ®Google Scholar
• Yokota SI, Kitahara M, Nagata K. Benzylidene lactam compound, KNK437, a novel inhibitor of acquisition of thermotolerance and heat shock protein induction in human colon carcinoma cells. Cancer Res. 2000;60:2942–2948.
   PubMed Web of Science ®Google Scholar
• Leith JT, Heyman P, DeWyngaert JK, et al. Thermal survival characteristics of cell subpopulations isolated from a heterogeneous human colon tumor. Cancer Res. 1983;43:3240–3246.
   PubMed Web of Science ®Google Scholar
• Koishi M, Hosokawa N, Sato M, et al. Quercetin, an inhibitor of heat shock protein synthesis, inhibits the acquisition of thermotolerance in a human colon carcinoma cell line. Jpn J Cancer Res. 1992;83:1216–1222.
   PubMedGoogle Scholar
• Lepock JR, Kruuv J. Thermotolerance as a possible cause of the critical temperature at 43 in mammalian cells. Cancer Res. 1980;40:4485–4488.
   PubMed Web of Science ®Google Scholar
• Raaphorst GP, Mao J, Ng CE. Thermotolerance in human glioma cells. Int J Hyperthermia. 1995;11:523–529.
   PubMed Web of Science ®Google Scholar
• Sapareto SA, Hopwood LE, Dewey WC, et al. Effects of hyperthermia on survival and progression of Chinese hamster ovary cells. Cancer Res. 1978;38:393–400.
   PubMed Web of Science ®Google Scholar
• He X, Bischof JC. Quantification of temperature and injury response in thermal therapy and cryosurgery. Crit Rev Biomed Eng. 2003;31:355–422.
   PubMedGoogle Scholar
• Pearce JA. Comparative analysis of mathematical models of cell death and thermal damage processes. Int J Hyperthermia. 2013;29:262–280.
   PubMed Web of Science ®Google Scholar
• Wang CC, Chen F, Kim E, et al. Thermal sensitization through ROS modulation: a strategy to improve the efficacy of hyperthermic intraperitoneal chemotherapy. Surgery. 2007;142:384–392.
   PubMed Web of Science ®Google Scholar
• Lehmann K, Rickenbacher A, Jang JH, et al. New insight into hyperthermic intraperitoneal chemotherapy: induction of oxidative stress dramatically enhanced tumor killing in in vitro and in vivo models. Ann Surg. 2012;256:730–738.
   PubMed Web of Science ®Google Scholar
• Solazzo SA, Ahmed M, Schor-Bardach R, et al. Liposomal doxorubicin increases radiofrequency ablation–induced tumor destruction by increasing cellular oxidative and nitrative stress and accelerating apoptotic pathways. Radiology. 2010;255:62–74.
   PubMed Web of Science ®Google Scholar
• Wang S, Konorev EA, Kotamraju S, et al. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms intermediacy of H2O2-and p53-dependent pathways. J Biol Chem. 2004;279:25535–25543.
   PubMed Web of Science ®Google Scholar
• Schoenfeld JD, Sibenaller ZA, Mapuskar KA, et al. O2⋅− and H2O2-mediated disruption of Fe metabolism causes the differential susceptibility of NSCLC and GBM cancer cells to pharmacological ascorbate. Cancer Cell. 2017;31:487–500.
   PubMed Web of Science ®Google Scholar